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Background: Pharmacological activation of type-2 metabotropic glutamate receptors (mGlu2 receptors) causes
analgesia in experimental models of inflammatory and neuropathic pain. Presynaptic mGlu2 receptors are activated
by the glutamate released from astrocytes by means of the cystine/glutamate antiporter (System xc
- or Sxc
- ). We
examined the analgesic activity of the Sxc
- activator, N-acetyl-cysteine (NAC), in mice developing inflammatory or
neuropathic pain.
Results: A single injection of NAC (100 mg/kg, i.p.) reduced nocifensive behavior in the second phase of the
formalin test. NAC-induced analgesia was abrogated by the Sxc
- inhibitor, sulphasalazine (8 mg/kg, i.p.) or by the
mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.). NAC still caused analgesia in mGlu3−/− mice, but was
inactive in mGlu2−/− mice. In wild-type mice, NAC retained the analgesic activity in the formalin test when injected
daily for 7 days, indicating the lack of tolerance. Both single and repeated injections of NAC also caused analgesia
in the complete Freund’s adjuvant (CFA) model of chronic inflammatory pain, and, again, analgesia was abolished
by LY341495. Data obtained in mice developing neuropathic pain in response to chronic constriction injury (CCI) of
the sciatic nerve were divergent. In this model, a single injection of NAC caused analgesia that was reversed by
LY341495, whereas repeated injections of NAC were ineffective. Thus, tolerance to NAC-induced analgesia
developed in the CCI model, but not in models of inflammatory pain. The CFA and CCI models differed with
respect to the expression levels of xCT (the catalytic subunit of Sxc
- ) and activator of G-protein signaling type-3
(AGS3) in the dorsal portion of the lumbar spinal cord. CFA-treated mice showed no change in either protein,
whereas CCI mice showed an ipislateral reduction in xCT levels and a bilateral increase in AGS3 levels in the
spinal cord.
Conclusions: These data demonstrate that pharmacological activation of Sxc
- causes analgesia by reinforcing the
endogenous activation of mGlu2 receptors. NAC has an excellent profile of safety and tolerability when clinically
used as a mucolytic agent or in the management of acetaminophen overdose. Thus, our data encourage the use of
NAC for the experimental treatment of inflammatory pain in humans.
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Group-II metabotropic glutamate receptors (mGlu2
and mGlu3 receptors) regulate pain threshold and are
considered as potential targets for novel analgesic
drugs [1-3]. mGlu2/3 receptors regulate pain transmis-
sion at different levels of the pain neuraxis. In periph-
eral nociceptors, mGlu2/3 receptors inhibit pain
transmission by restraining the activation of TRPV1
receptors and tetrodotoxin-resistant voltage-sensitive
sodium channels [4-6]; in the dorsal horns of the
spinal cord, mGlu2/3 receptors are presynaptically
localized on primary afferent fibers, where they nega-
tively modulate neurotransmitter release [7,8]. These
receptors also regulate pain threshold in the periaque-
ductal grey and amygdala [9,10]. Recent findings sug-
gest that analgesia caused by mGlu2/3 receptor
agonists is primarily mediated by the activation of
mGlu2 receptors [11]. However, mGlu3 receptors may
also contribute to the regulation of pain threshold as
suggested by the evidence that (i) mGlu3 receptors are
up-regulated in the spinal cord and cerebral cortex in
models of peripheral inflammation and hyperalgesia
[12-14]; and (ii) the putative mGlu3 agonist, N-
acetylaspartylglutamate (NAAG), or inhibitors of
NAAG degradation cause analgesia in models of in-
flammatory or neuropathic pain [15-21]. Taken to-
gether, these data set the ground for the development
of mGlu2/3 receptor agonists or mGlu2 receptor
PAMs (positive allosteric modulators) as novel anal-
gesic drugs [1-3]. However, a major pitfall associated
with the use of mGlu2 receptor agonists for pain treat-
ment is the development of tolerance, which occurs
after only 4–5 days of repeated dosing [22,23]. One
way to overcome this limitation is to enhance the ex-
pression of mGlu2 receptors. L-Acetylcarnitine (LAC)
and histone deacetylase (HDAC) inhibitors cause anal-
gesia without the development of tolerance by select-
ively increasing mGlu2 receptor expression in dorsal
root ganglia (DRG) neurons and dorsal horns of the
spinal cord. Both classes of drugs enhance transcrip-
tion of the Grm2 gene encoding mGlu2 receptor by
acetylating p65/RelA, a member of the Nuclear Factor-
κB (NFκB) family of transcription factors [1,23-25].
This finding contributes to explain the clinical efficacy
of LAC in painful peripheral neuropathies [26-29] and
holds promise for a potential use of HDAC inhibitors
in the treatment of chronic pain. An alternative strat-
egy is to reinforce the endogenous activation of mGlu2
receptors, considering that these receptors are mainly,
albeit not exclusively, localized in the preterminal re-
gion of axon terminals and have limited access to syn-
aptic glutamate [30]. The L-cystine/L-glutamate
membrane exchanger (System xc
- or Sxc
-), which med-
iates non-vesicular release of glutamate from astrocytesand microglia, represents a potential source for en-
dogenous activation of presynaptic mGlu2/3 receptors
[31]. Sxc
- is a membrane antiporter that mediates the
chloride-dependent, sodium-independent, 1:1 exchange
of extracellular L-cystine and intracellular L-glutamate,
and provides the intracellular L-cysteine required for
the synthesis of glutathione. Similarly to other mem-
bers of heteromeric amino acid transporter family, Sxc
-
is formed by a heavy chain 4F2hc subunit and a light
chain xCT (SLC7A11) subunit. The xCT subunit med-
iates the transport of cystine and glutamate across the
plasma membrane [32]. We hypothesized that drugs
that promote Sxc
- activity, such as N-acetyl-cysteine
(NAC) [32], could enhance the endogenous activation
of mGlu2 receptors in the pain neuraxis, thereby pro-
ducing analgesia.
Here, we report that systemic administration of
NAC causes robust analgesia in mouse models of inflam-
matory and neuropathic pain, and that NAC acts by re-
inforcing the endogenous activation of mGlu2 receptors.
Results
Activation of Sxc
- by NAC causes analgesia in the second
phase of the formalin test
In a first set of experiments we assessed the analgesic ac-
tivity of NAC in the formalin model of inflammatory
pain. A single injection of NAC (100 mg/kg, i.p.; 30 min
before the test) did not affect the first phase of nocifen-
sive behavior, which reflects peripheral inflammatory
pain. In contrast, NAC caused robust analgesia
in the second phase of the formalin test (F(5,37) = 25,63;
p < 0.001), which involves mechanisms of central
sensitization in the dorsal horns of the spinal cord
[33,34] (Figure 1A). To study the involvement of Sxc
-
in the action of NAC, we used the Sxc
- inhibitor
sulphasalazine [35]. Because sulphasalazine is converted
into the anti-inflammatory/analgesic drug, 5-
aminosalycilic acid [35], we first tested different doses of
sulphasalazine alone in the formalin test. Sulphasalazine
caused analgesia at doses of 25, 50 or 100 mg/kg, i.p.
(not shown), but not at doses <10 mg/kg, i.p.. NAC-
induced analgesia was abrogated by a 15-min pretreat-
ment with 8 mg/kg of sulphasalazine (p < 0.001), or with
the orthosteric mGlu2/3 receptor antagonist, LY341495
(1 mg/kg, i.p.) (p < 0.001) (Figure 1A). Neither
sulphasalazine nor LY341495 influenced nocifensive be-
havior on their own (Figure 1A). The action of NAC was
also examined in mGlu2−/− mice and their wild-type lit-
termates. As expected [11], mGlu2−/− mice showed an
enhanced nocifensive behavior in the second phase of
the formalin test, as compared to wild-type mice
(strain x treatment interaction: F(1,16) = 12,96; p = 0.002)
(Figure 1B). A single injection of NAC failed to cause
analgesia in mGlu2−/− mice (Figure 1B). We extended
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Figure 1 Single and repeated injections of NAC cause analgesia in the phase II of the formalin test. Nocifensive behavior of mice treated
i.p. with a single injection of NAC (100 mg/kg) or saline preceded, 15 min earlier, by saline, sulphasalazine (8 mg/kg), or LY341495 (1 mg/kg) is
shown in (A). Values are means ± SEM of 5–12 mice per group. p < 0.05 vs. all other groups of phase II (One-way ANOVA + Holm-Sidak’s test).
Nocifensive behavior of mGlu2−/− or mGlu3−/− mice and their wild-type littermates treated i.p. with a single injection of NAC (100 mg/kg) or
saline is shown in (B) and (C), respectively. Values are means ± SEM of 5 mice per group. p < 0.05 (Two-way ANOVA + Holm-Sidak’s test)
vs. wild-type mice injected with saline alone (#) or vs. the corresponding groups of wild-type mice (*). Nocifensive behavior of normal mice
treated i.p. with repeated injections of NAC (100 mg/kg) or saline, once a day for 7 days, is shown in (D). Values are means ± SEM of 6 mice per
group. *p < 0.05 (Student’s t test) vs. phase II values of mice treated with saline. Motor performance of mice treated with single or repeated
injections of NAC or saline on the accelerating rotarod is shown in (E). Values are means ± S.E.M. of 5 mice per group.
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mates from a CD1 genetic background. As opposed to
data obtained in mGlu2−/− mice, NAC fully retained its
analgesic activity in mice lacking mGlu3 receptors (sec-
ond phase of the formalin test: strain x treatment inter-
action: F(1,16) = 35.738; p < 0.001) (Figure 1C).
To examine whether tolerance could develop to the
analgesic activity of NAC, mice were treated with NAC
(100 mg/kg, i.p.) once a day for 7 days, with the test
being performed 30 min after the last injection.
Repeated injections of NAC still caused analgesia in the
second phase of the formalin test (t(12) = 9,68; p < 0.001)
(Figure 1D), suggesting the lack of tolerance.To exclude that measurements of the analgesic activity
of NAC could be biased by changes in motor activity we
assessed motor coordination in mice receiving single or
repeated injections of NAC using the rotarod test. Con-
trol mice were treated with saline i.p. once a day for
7 days. One group of mice received saline for 6 days fol-
lowed by NAC (100 mg/kg, i.p.) on the 7th day. Another
group of mice was treated with NAC once a day for
7 days. Motor behavior was assessed for 5 consecutive
trials (with intervals of 5 min), starting 30 min following
the last injection. Motor performance was unaffected by
single or repeated injections of NAC in the five trials
(Figure 1E).
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(CFA) model of chronic inflammatory pain via the
activation of mGlu2 receptors
We extended the study to the CFA model of chronic in-
flammatory pain in mice receiving single or repeated
injections of NAC. In acute experiments, NAC (100 mg/
kg, i.p.) was administered only once, at day 7 following
unilateral intraplantar injection of CFA. In chronic
experiments, NAC was administered daily starting 4 h
following CFA injection. Mechanical thresholds were
measured after 7 days of treatment always 30 min fol-
lowing the last injection of NAC or saline. Both single
and repeated injections of NAC caused a robust anal-
gesia in the CFA model of chronic pain (CFA/vehicle x
acute drug treatment: F(3,64) = 3.46; p = 0.021; CFA/
vehicle x repeated drug administrations: F(3,64) = 3.77 p =
0.015) (Figure 2A,B). Again, the action of NAC was
abrogated by LY341495 (1 mg/kg, i.p.), given 15 min be-
fore NAC in acute experiments, or 15 min before the
last administration of NAC in chronic experiments
(Figure 2A,B). Thus, a single injection of LY341495 was
sufficient to abolish analgesia induced by repeated injec-
tions of NAC (Figure 2B).
Single injection, but not repeated injections, of NAC
causes analgesia in the chronic constriction injury (CCI)
model of neuropathic pain
Mice were subjected to unilateral CCI of the sciatic
nerve and tested for mechanical pain thresholds after
14 days. A single injection of NAC (100 mg/kg, i.p.) sig-
nificantly increased pain thresholds in CCI mice (CCI/

































Figure 2 Single and repeated injections of NAC cause analgesia in th
vehicle (saline) or CFA in the right hind paw, and tested for mechanical pa
injection of NAC (100 mg/kg) or saline preceded, 15 min earlier, by saline o
for 7 days. Either saline or LY341495 (1 mg/kg) were injected i.p. 15 min pr
means ± SEM of 9 mice per group. p < 0.05 (Two-way ANOVA + Holm-Sidak
vehicle (saline) in the hind paw (*), or vs. all other groups of CFA mice (#).0.001). Again, the action of NAC was abrogated by a
15-min pretreatment with LY341495 (1 mg/kg, i.p.),
which was inactive on its own (Figure 3A). In the CCI
model, repeated injections of NAC failed to induce anal-
gesia (CCI/SO x drug treatment: F(1,41) = 0.14; p > 0.05),
suggesting that neuropathic pain facilitates the develop-
ment of tolerance to the action of NAC (Figure 3B).
The activation machinery of mGlu2 receptors is impaired
in the CCI model of neuropathic pain but not in the CFA
model of chronic inflammatory pain
Searching for mechanisms that could explain the refrac-
toriness of CCI mice to repeated injections of NAC, we
measured the levels of (i) mGlu2/3 receptors; (ii) the
xCT catalytic subunit of the cystine/glutamate antipor-
ter; and (iii) the Gi-protein regulator, type-3 activator of
G-protein signaling (AGS3). Immunoblot analysis of
mGlu2/3 receptors showed two bands at 100 kDa and
>200 kDa corresponding to receptor monomers and
dimers, respectively (see representative immunoblot in
Figure 4A). In CCI mice, we found no changes in the ex-
pression of mGlu2/3 receptors in the contralateral and
ipsilateral dorsal portions of the lumbar spinal cord after
14 days (Figure 4A). In contrast, the expression of xCT
(detected as a single band at the expected molecular size
of 55 kDa) was reduced ipsilaterally in the dorsal region
of the lumbar spinal cord of CCI mice as compared to
the ipsilateral region of SO mice (SO x CCI: F(1,20) = 7.25
p = 0.014; CCI/SO x ipsilateral/contralateral: F(1,20) =
0.47; p > =0.05) (Figure 4B). AGS3 (identified as a band
at 75 kDa), which negatively regulates the Gαi-mediated
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Figure 3 Single injection of NAC causes analgesia in the CCI model of neuropathic pain. (A), Mechanical allodynia analysis of CCI mice
(14 days after surgery). In (A) mice were treated i.p. with a single injection of NAC (100 mg/kg) or saline preceded, 15 min earlier, by saline or
LY341495 (1 mg/kg). In (B), mice were treated i.p. with saline or NAC for 7 days. Either saline or LY341495 (1 mg/kg) were injected i.p. 15 min
prior to the last injection of NAC or saline. In both (A) and (B), values are means ± SEM of 11 mice per group. p < 0.05 (Two-way
ANOVA + Holm-Sidak’s test) vs. the respective groups of sham operated (SO) mice (*), or vs. all other groups of CCI mice (#).
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mice (CCI x SO: F(1,28) = 1.046E + 002; p < 0.001; ipsilat-
eral x contralateral: F(1,28) = 9.78 p = 0.004; CCI/SO x ip-
silateral/contralateral: F(1,28) = 3,47 p > 0.05) (Figure 4C).
The up-regulation of the AGS3 protein in the spinal
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Figure 4 Changes in xCT and AGS3 levels in the lumbar spinal cord o
mGlu2/3 receptors, xCT, and AGS3 in the ipsilateral (ipsi) and contralateral (
animals (SO) and CCI mice is shown in (A), (B), and (C), respectively. AGS3
Values are means ± S.E.M. of 6–8 individual determinations (from 2 groups
respective values of SO mice (*), or vs. values of the ipsilateral side of CCI mAGS3 mRNA levels in the DRG (the site of production
of AGS3 present in the primary afferent fibers), although
a trend to an increase was seen in the ipsilateral side
(Figure 4D). Interestingly, levels of mGlu2/3 receptors,
xCT, and AGS3 were unaltered in the spinal cord of
CFA mice (Figure 5A-C).a
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Figure 5 Levels of mGlu2/3 receptors, xCT and AGS3 in the lumbar spinal cord of mice developing chronic inflammatory pain. Same as
in Figure 4, with the difference that mice were injected with vehicle (saline) or CFA in the hind paw. Values are means ± S.E.M of 6 mice per
group.
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Recent evidence highlights the role of glial Sxc
- in regu-
lating the homeostasis of extracellular glutamate in the
CNS, thereby contributing to physiological and patho-
logical processes driven by ionotropic or metabotropic
glutamate receptors. For example, Sxc
- -mediated efflux
of glutamate from glioma cells provides a signal that
allows tumor cell growth and migration via the activa-
tion of Ca2+-permeable AMPA receptors [36,37]. Peter
Kalivas (University of South Caroline) and his colleagues
have shown cocaine addiction in rats causes a down-
regulation of Sxc
- and an up-regulation of AGS3, which
both impair mGlu2/3 receptor signaling in the nucleus
accumbens core. Treatment with NAC reverses cocaine-
induced metaplasticity, and inhibits cocaine seeking [38-41].
Remarkably, NAC also reduces cocaine craving in
humans [42], suggesting that the strategy to reinforce
mGlu2/3 signaling can be applied to human pathology.
Here, NAC caused robust analgesia in models of in-
flammatory and neuropathic pain, and its action was
sensitive to mGlu2/3 receptor blockade. In the formalin
model, NAC did not cause analgesia in mice lacking
mGlu2 receptors, but retained its activity in mice lacking
mGlu3 receptors. Thus, at least in the formalin model,
the action of NAC appeared to be mediated by mGlu2
receptors. These findings are intriguing because mGlu3
receptors also contribute to the regulation of pain trans-
mission (see Introduction and references therein), andare expected to be activated by the glutamate released
from astrocytes via the cystine/glutamate antiporter.
One possible explanation is that the mGlu3 receptor,
which has a high affinity for glutamate, is saturated by
the ambient glutamate and cannot be further activated
by drug that enhances glutamate release from astrocytes.
However, the evidence that nocifensive behavior was not
amplified in mGlu3−/− mice (as opposed to mGlu2−/−
mice) (see also ref. 11) calls into question the role of
mGlu3 receptors in the endogenous regulation of pain
transmission. Another interesting finding was that NAC
reduced nocifensive behavior exclusively in the second
phase of the formalin test, whereas mGlu2/3 receptor
agonists also cause analgesia in the first phase of the
test, providing that the mGlu2 receptor is present [11].
We speculate that the action of mGlu2/3 receptor ago-
nists in the first phase of the formalin test is mainly
mediated by mGlu2 receptors expressed on peripheral
nociceptors [4,43-45], which may not be targeted by the
glutamate released via the glutamate/cystine antiporter.
The second phase of the formalin test reflects mechan-
isms of nociceptive sensitization in the dorsal horns of
the spinal cord [33,34], where mGlu2 receptors are likely
to be activated by the glutamate released from astro-
cytes. To demonstrate that NAC caused analgesia by in-
creasing Sxc
- activity, we used the drug sulphasalazine in
the formalin model. The pharmacology of Sxc
- is nicely
reviewed by Bridges et al. [32]. (S)-4-Carboxyphenylglycine
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[46,47] and sulphasalazine [35] are among the most
potent inhibitors of Sxc
-. We could not use 4-S-CPG or
4C3HPG because these drugs can also activate mGlu2/3
receptors [48]. Sulphasalzine is a pro-drug containing
sulphapyridine and 5-amino salicylic acid, which is widely
used in the clinic for the oral or rectal treatment of in-
flammatory bowel disorders [49]. Because significant
amounts of 5-amino salicylic acid can be released in re-
sponse to i.p. injection of sulphasalazine, we first searched
for a dose of sulphasalazine that was not analgesic per se.
At the dose of 8 mg/kg, sulphasalazine did not influence
nocifensive behavior on its own, but abrogated the anal-
gesic activity of NAC indicating that NAC acted by stimu-
lating Sxc
- activity.
An intriguing finding was that no tolerance to NAC-
induced analgesia developed in models of inflammatory
pain, whereas repeated administrations of NAC failed to
induce analgesia in the CCI model of neuropathic pain.
We searched for molecular events that could have lim-
ited analgesia in response to repeated injections of NAC
by measuring the levels of mGlu2/3 receptors, xCT and
AGS3 in the ipsi- and contralateral dorsal regions of the
spinal cord of CFA and CCI mice. Interestingly, CFA
mice did not show changes in the levels of any of these
proteins, whereas CCI mice showed a reduced expres-
sion of xCT ipsilaterally, and an increased expression of
AGS3 bilaterally. AGS3 is a member of a family of G-
protein regulators that influence nucleotide exchange at
the α subunit of Gi/o proteins [50]. AGS3 stabilizes Gαi
in the GDP-bound inactive configuration, thereby inhi-
biting Gαi-mediated transduction mechanisms in spite
of its name (AGS stands for “activator of G-protein sig-
naling”) [50]. mGlu2/3 receptors are coupled to Gi/Go
proteins, and their activation negatively modulates ade-
nylyl cyclase activity [30]. It is possible that, in the CCI
model, unidentified adaptation responses to NAC devel-
oped in a context of neuroplastic changes limiting the
endogenous activation of mGlu2 receptors (i.e., a
reduced expression of xCT and an increased expression
of AGS3). This may cause refractoriness to repeated
injections of NAC. In contrast, adaptation responses to
NAC would not be sufficient to cause tolerance in the
CFA model of inflammatory pain, in which the endogen-
ous machinery of mGlu2 receptor activation was appar-
ently intact. Further studies are needed to identify the
precise mechanism by which tolerance to NAC develops
in models of neuropathic pain, but not in models of in-
flammatory pain.
Conclusions
In conclusion, these data demonstrate that the strategy
of reinforcing the endogenous activation of mGlu2
receptors can be successfully applied to the treatment ofpain. NAC is widely used in the clinic as a mucolytic
agent, as well as in the treatment of acetaminophen
poisoning and contrast-medium-induced nephropathy
[51-54]. The excellent safety profile of NAC makes this
drug a novel potential candidate for the experimental





and formaldehyde were purchased from Sigma Aldrich
(Milano, Italy). (2S)-2-Amino-2-[(1S,2S)-2-carboxycyclo-
prop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495) was
purchased from Tocris Cookson (Avonmouth, Bristol,
UK).
Animals
All experiments were carried out according to the Euro-
pean (86/609/EEC) and Italian (D: Lgs. 116/92) guide-
lines of animal care. The experimental protocol was
approved by the Italian Ministry of Health. All efforts
were made to minimize animal suffering and the number
of animals used. In most of the experiments, we used
adult male C57BL/6 J mice (20–25 g, b.w.) purchased
from Charles River (Calco, Italy). We also used mGlu2
and mGlu3 receptor knockout mice (mGlu2−/− and
mGlu3−/− mice). mGlu2−/− mice from a C57BL/6 J gen-
etic background were generated in the laboratory of
Prof. Shigetada Nakanishi at Kyoto University, Japan.
Knockout mice were backcrossed with C57BL/6 J wild-
type mice for the generation of mGlu2+/− mice. mGlu3−/−
mice from a CD1 genetic background were kindly pro-
vided by Eli Lilly and Company (IN, USA). Knockout
mice were backcrossed with CD1 wild-type mice for the
generation of mGlu3+/− mice. All mice were individually
genotyped for the mGlu2 and mGlu3 receptor gene by
PCR. Knockout mice and their wild-type littermates gen-
erated by heterozygous crosses were used for the assess-
ment of nocifensive behavior in the formalin test. All
mice were housed 5 for cages, under a standard 12/12 h
light/dark cycle with food and water ad libitum.
Formalin test
Acute inflammatory pain was assessed using the forma-
lin test. Ten μl of a formalin solution (2% for C57BL/6 J
mice and 5% for CD1 mice) was injected s.c. into the
plantar surface of the right hind paw. After injection,
mice were immediately placed in a plexiglass box (20 ×
15 × 15 cm) surrounded by mirrors to allow the observa-
tion of nociceptive responses that include licking, lifting
and shaking of the injected paw. Tests were performed
between 08:00 h and 12:00 h to minimize variability.
After formalin injection, mice were observed for 1 h and
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genotypes and drug treatments. Formalin scores were
separated into two phases, phase I (0–10 min) and phase
II (20–60 min). The mean behavioral score was calcu-
lated in blocks of 5 min for each of the two phases. A
mean response was then calculated for each phase [11].
In acute experiments, 6 groups of mice (n = 5–12 per
group) were treated i.p., as follows: (i) one injection of
saline followed by another injection of saline; (ii) one in-
jection of NAC (100 mg/kg) followed by one injection of
saline; (iii) one injection of LY341495 (1 mg/kg) followed
by one injection of saline; (iv) one injection of sulphala-
zine (8 mg/kg) followed by one injection of saline; (v)
one injection of LY341495 followed by one injection of
NAC; and (vi) one injection of sulphalazine followed by
one injection of NAC. In all groups the two injections
were performed with 15 min of interval. Formalin was
injected in the hind paw 30 min after the second i.p. in-
jection. In chronic experiments, 2 groups of 6 mice were
treated daily i.p. with saline or NAC (100 mg/kg) for
7 days. Formalin was injected 30 min after the last
injection of saline or NAC. Two additional groups of
mGlu2−/− mice and two groups of wild-type littermates
(n = 5 per group) received a single i.p. injection of saline
or NAC (100 mg/kg) 30 min prior to formalin injection.
The CFA model of chronic inflammatory pain
Tissue inflammation was induced by s.c. injections of
20 μl of Complete Freund’s Adjuvant (CFA, F5881
Sigma-Aldrich; 1 mg/ml) in the dorsal surface of the
right hind paw; control mice were injected s.c. with sa-
line in the right hind paw. Mechanical pain thresholds
were assessed with von Frey filaments (see below) 7 days
after injection of CFA or vehicle (saline) in the hind
paw. For acute experiments, 4 groups of control and 4
groups of CFA-injected mice (n = 9 mice per group)
were treated i.p. as follows: (i) one injection of saline fol-
lowed by another injection of saline; (ii) one injection of
NAC (100 mg/kg) followed by one injection of saline;
(iii) one injection of LY341495 (1 mg/kg) followed by
one injection of saline; (iv) one injection of LY341495
followed by one injection of NAC. The two i.p. injec-
tions were carried out with 15 min of interval. All treat-
ments were performed at day 7 after vehicle or CFA
injections in the hind paw, with the second i.p. injection
being performed 30 min prior to the assessment of
mechanical pain thresholds. For chronic treatments,
4 groups of control and 4 groups of CFA-injected mice
(n = 9 per group) were treated using the same protocol
of acute experiments with the difference that drugs were
injected daily for 7 days starting 10 min following CFA
(or saline) injection. Mechanical pain thresholds were
measured 30 min after the last i.p. injection. One add-
itional group of control mice and one additional groupof CFA-injected mice (n = 6 per group) were used for
biochemical experiments. These mice were tested for
mechanical pain thresholds at day 7, and killed after 6 h.
Induction of chronic constriction injury (CCI) of the
sciatic nerve
Seventy-four mice subjected to CCI of the sciatic nerve,
and 74 sham operated (SO) mice were used for pharma-
cological experiments. All selected CCI mice did not dis-
play gross deficits in motor behavior that might have
influenced the assessment of mechanical allodynia.
Chronic constriction of the sciatic nerve was carried
out under pentobarbital anesthesia (50 mg/kg, i.p.), as
described by Bennett and Xie [55]. In brief, the biceps
femoris and the gluteus superficialis were separated by
blunt dissection, and the left sciatic nerve was exposed.
CCI was produced by tying two ligatures around the sci-
atic nerve. The ligatures were tied loosely around the
nerve with 1 mm spacing, until they elicited a brief
twitch in the respective hind limb, which prevented
over-tightening of the ligations, taking care to preserve
epineural circulation. The incision was cleaned and the
skin was closed with 2–3 ligatures of 5–0 dermalon.
Mice were then placed on a warmed surface and, follow-
ing recovery, they were returned to their home cages
and checked routinely for 72 h. In SO mice, the left sci-
atic nerve was exposed without ligature. Mechanical
allodynia (see below) was assessed 14 days after surgery.
The development of mechanical allodynia was evaluated
by using the von Frey filaments. All animals were tested
before surgery and then 14 days after surgery. Six groups
of CCI mice and 4 groups of SO mice (n = 11 per group)
were used for pharmacological experiments with NAC
and/or LY341495. One group of CCI mice and one
group of SO mice (n = 8 per group) were used for bio-
chemical analysis. For pharmacological experiments, the
following groups of SO or CCI mice were treated i.p. as
follows. Acute experiments: (i) one injection of saline
followed by another injection of saline; (ii) one injection
of saline followed by one injection of NAC (100 mg/kg);
(iii) one injection of LY341495 (1 mg/kg) followed
by one injection of saline; and (iv) one injection
of LY341495 followed by one injection of NAC. The two
i.p. injections were separated by a 15-min interval.
Chronic experiments: (i) daily injections with saline for
7 days; and (ii) daily injections with NAC (100 mg/kg)
for 7 days. In acute experiments, pain thresholds were
measured 1 h after the last injection. In chronic experi-
ments, treatment started on day 7 after surgery, and pain
thresholds were measured 1 h after the last injection.
For biochemical experiments, one additional group of
SO and one additional group of CCI mice (n = 8 per
group) were tested for mechanical thresholds at 14 days,
and killed after 6 h.
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Mechanical allodynia was quantified by measuring the
hind paw withdrawal response to von Frey filament
stimulation. In brief, animals were placed in a PlexiglasW
box (20 cm high, 9 cm diameter) with a wire grid bot-
tom through which the von Frey filaments (North Coast
Medical, Inc., San Jose, CA, USA) bending force range
from 0.008 to 3.5 g, were applied by using a modified
version of the up-down paradigm, as previously reported
by Chaplan [56]. The filaments were applied 5 times
each, in order of increasing forces, and pressed perpen-
dicularly to the plantar surface of the hindpaw until
they bent. The first filament which evoked at least 3
responses was assigned as the pain threshold in grams.
For the assessment of mechanical sensitivity, mice were
placed in individual cages with elevated mesh floor 1 h
before all behavioral testing. Mechanical allodynia was
determined with a set of calibrated von Frey filaments
used to stimulate the dorsal side of both right and left
paws.
Assessment of motor performance by the rotarod test
The rotarod apparatus consisted of a rotating horizontal
cylinder (30 mm) and a motor driver control unit (Ugo
Basile, Varese, Italy). The cylinder was divided into five
separate rotating compartments and fully enclosed to
ensure that the mice did not jump out of their area.
Mice were placed on the rod, which was rotating at an
accelerating speed from 4 to 40 rpm in 5 min. The time
the mice remained on the rod was automatically
recorded by timers. Five mice for each group were trea-
ted with single or repeated i.p. injection of saline and
NAC (100 mg/kg). Thirty minutes later mice were
placed on the rotarod apparatus and five consecutive ac-
celeration trials were carried out with an interval of five
min between each trial.
Biochemical experiments
Western blot analysis
The dorsal portions of the lumbar spinal cord containing
the dorsal horns were dissected out and homogenized at
4 °C in Tris–HCl buffer, containing 1 mM PMSF, pH
7.4, and an aliquot was used for protein determinations.
Equal amounts of proteins (30 μg) from supernatants
were separated by 8% SDS polyacrilamide gel for the de-
tection of mGlu2/3 receptor, while for the detection of
xCT and AGS3 proteins was used 10% SDS polyacrila-
mide gel. After separation, proteins were transferred on
immuno-blot PVDF membranes. Filters were blocked
for 2 h at 4 °C in TTBS buffer containing 5% non-fat dry
milk. mGluR2/3 was labeled using anti-Glutamate Re-
ceptor 2/3, Metabotropic (mGluR2/3) produced in rabbit
(1:1000, Sigma) and secondary anti-rabbit antibody (per-
oxidase-coupled antirabbit 1:7.000 Calbiochem, Milano,Italy). Blots for xCT were incubated overnight at 4 °C
with the respective antibodies: anti Mouse Cystine/Glu-
tamic Acid Trasporter (xc-), (1:1.500, rabbit polyclonal,
Transgenic, Tokyo, Japan). Filters were washed three
times with TTBS buffer and then incubated for 1 h with
secondary antibodies (peroxidase-coupled anti-rabbit
1:7.000 Calbiochem, Milano, Italy). Blots for AGS3 were
incubated with the goat polyclonal antibody for AGS3
(1:500, AGS3 (A-20): sc-1639, Santa Cruz Biotechnology,
Inc. CA, USA). Filters were washed three times
with TTBS buffer and then incubated for 1 h with sec-
ondary antibodies (peroxidase-coupled donkey anti-goat
1:5.000, Santa Cruz Biotechnology, Inc., Temecula, CA,
USA). Immunostaining was revealed by enhanced-
chemiluminescence luminosity (Amersham Pharmacia
Biotech, Arlington Height, IL). The blots were reprobed
with anti-β-actin monoclonal antibody (1:250, Sigma,
St. Louis, MO).
Real-time RT-PCR
DRGs were dissected bilaterally, and total RNA was iso-
lated using the TRIzol reagent (Invitrogen) according to
the manufacturer’s protocol and retrotranscribed into
cDNA by using SuperScript III Reverse Transcriptase
(Invitrogen). Real-Time RT-PCR was performed on the
Step One Plus Applied Biosystems. PCR was performed by
using Power SYBR Green PCR Master Mix Kit (Applied
Biosystems) according to the manufacturer’s instructions.
Thermal cycler conditions were as follows: 5 min at 50 °C,
2 min at 95 °C, 40 cycles of denaturation (45 s at 95 °C),
and combined annealing/extension (1 min at 60 °C). The
sequences of GAPDH and AGS3 primers used were:
GAPDH forward 50-CGTCCCGTAGACAAAATGGT-30
and reverse 50- TCAATGAAGGGGTCGTTGAT-30;
AGS3 forward 50-TGCGGCACCTAGTCATTGC-30 and
50- TGTCAGTTCTCCGTTTCGGTC-30. Concentrations
of mRNA were calculated from serially diluted standard
curves simultaneously amplified with the samples and
normalized with respect to GAPDH mRNA levels.
Statistical analysis
Statistical analysis was carried out by using the Student’s t
test (Figure 1D); One-Way ANOVA (Figure 1A) or Two-
Way ANOVA (all other Figures) followed by Holm-Sidak’s
test. p values <0.05 were considered significant.
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